Abstract:Ra-223 is an alpha-emitter approved for the treatment of bone metastatic prostate cancer (PCa), which exerts direct cytotoxicity toward PCa cells near the bone interface, whereas cells positioned in the core respond poorly because of short alpha-particle penetrance. beta 1 integrin (beta 1I) interference has been shown to increase radiosensitivity and significantly enhance external-beam radiation efficiency. We hypothesized that targeting beta 1I would improve Ra-223 outcome. Methods: We tested the effect of combining Ra-223 and anti-beta 1I antibody treatment in PC3 and C4-2B PCa cell models expressing high and low beta 1I levels, respectively. In vivo tumor growth was evaluated through bioluminescence. Cellular and molecular determinants of response were analyzed by ex vivo 3-dimensional imaging of bone lesions and by proteomic analysis and were further confirmed by computational modeling and in vitro functional analysis in tissue-engineered bone mimetic systems. Results: Interference with beta 1I combined with Ra-223 reduced PC3 cell growth in bone and significantly improved overall mouse survival, whereas no change was achieved in C4-2B tumors. Anti-beta 1I treatment decreased the PC3 tumor cell mitosis index and spatially expanded Ra-223 lethal effects 2-fold, in vivo and in silico. Regression was paralleled by decreased expression of radioresistance mediators. Conclusion: Targeting beta 1I significantly improves Ra-223 outcome and points toward combinatorial application in PCa tumors with high beta 1I expression.

Enhancing 223ra Treatment Efficacy by Anti-β1 Integrin Targeting.